Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Zimmer Biomet

ZBH Healthcare Unknown Updated July 29, 2026
$97.14
52W $79.12 – $108.29
56/100
24.7
0.46
AI Committee Verdict
Watch
Conviction: Contested · 50% agreement · 6 analysts
+2.1%
-10.4%
0.20:1
Contested

Is ZBH Bullish or Bearish?

Mixed. Innellis AI committee rates Zimmer Biomet (ZBH) Watch with a composite score of 56/100 , based on 6 analysts with 50% agreement. Last updated July 29, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +3.52 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -16.48 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case
  • Price-to-book of 1.4x is a discount to asset value — Value
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • EPS declining -14.6% YoY despite any revenue growth — Growth
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 29, 2026
Overall Committee Score
56/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 49%
of 93 Healthcare peers
Value Analyst bullish
70 / 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.4x is a discount to asset value
Growth Analyst neutral
44 / 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− EPS declining -14.6% YoY despite any revenue growth
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
62 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3206.65)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 56.5 to 56.5.

Comparing 2026-07-28 to 2026-07-29 (1 day apart).

Technical Analysis

RSI (14)
70.0
Neutral
MACD Histogram
0.259
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$85.83
Resistance
$97.77
Bollinger %B
1.02
Above Upper Band
Price vs Moving Averages
EMA 9
$91.64 Above
EMA 21
$90.50 Above
EMA 50
$89.26 Above
EMA 200
$90.83 Above

Fundamental Analysis

Valuation
87
Growth
55
Profitability
0
Financial Health
87
Cash Flow
38
Valuation
P/E Ratio 24.7×
P/B Ratio 1.47×
PEG Ratio -1.70
Dividend Yield 0.01%
52W High $108.29
52W Low $79.12
Quality & Growth
ROE 5.5%
ROA 3.0%
Gross Margin 70.0%
Operating Margin 15.6%
Revenue Growth YoY
Debt / Equity 0.59
AI Fundamental Assessment
P/E ratio of 24.7 (inexpensive relative to a 15-40x range); Price-to-book of 1.5x; PEG ratio of -1.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.0%; Net margin of 0.1%; Gross margin of 0.7%; Current ratio of 1.73 (healthy short-term liquidity); Debt-to-equity of 0.59; Free cash flow margin of 1.1% (thin cash generation); Free cash flow per share is positive (9.41); Most recent quarter beat estimates by 11.0%; 4 consecutive earnings beats; EPS growth decelerating (+27.4% -> -13.6% QoQ); Analyst estimates flat over recent quarters
Get the Full ZBH Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore ZBH Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime